Loading…

Mitochondrial DNA sequence variation and risk of glioma

•The mitochondrial genome (mtDNA) is polymorphic in human populations.•Inherited variants in mtDNA may play a role in cancer risk and progression.•Array-based genotyping of mtDNA variants in 2 epidemiologic studies of glioma.•Selected mtDNA haplogroups and common mtDNA variants associate with glioma...

Full description

Saved in:
Bibliographic Details
Published in:Mitochondrion 2022-03, Vol.63, p.32-36
Main Authors: Samanic, Claudine M., Teer, Jamie K., Thompson, Zachary J., Creed, Jordan H., Fridley, Brooke L., Burt Nabors, L., Williams, Sion L., Egan, Kathleen M.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c455t-ee1f888d755f5cfae5a7f354442c507d51046a6c525dfed094f7965d3bcad24c3
cites cdi_FETCH-LOGICAL-c455t-ee1f888d755f5cfae5a7f354442c507d51046a6c525dfed094f7965d3bcad24c3
container_end_page 36
container_issue
container_start_page 32
container_title Mitochondrion
container_volume 63
creator Samanic, Claudine M.
Teer, Jamie K.
Thompson, Zachary J.
Creed, Jordan H.
Fridley, Brooke L.
Burt Nabors, L.
Williams, Sion L.
Egan, Kathleen M.
description •The mitochondrial genome (mtDNA) is polymorphic in human populations.•Inherited variants in mtDNA may play a role in cancer risk and progression.•Array-based genotyping of mtDNA variants in 2 epidemiologic studies of glioma.•Selected mtDNA haplogroups and common mtDNA variants associate with glioma risk.•Complete mtDNA sequencing needed for study of rare and singleton variants. Malignant gliomas are the most common primary adult brain tumors, with a poor prognosis and ill-defined etiology. Mitochondrial DNA (mtDNA) sequence variation has been linked with certain cancers; however, research on glioma is lacking. We examined the association of common (minor allele frequency ≥ 5%) germline mtDNA variants and haplogroups with glioma risk in 1,566 glioma cases and 1,017 controls from a US case-control study, and 425 glioma cases and 1,534 matched controls from the UK Biobank cohort (UKB). DNA samples were genotyped using the UK Biobank array that included a set of common and rare mtDNA variants. Risk associations were examined separately for glioblastoma (GBM) and lower grade tumors (non-GBM). In the US study, haplogroup W was inversely associated with glioma when compared with haplogroup H (OR = 0.43, 95%CI: 0.23–0.79); this association was not demonstrated in the UKB (OR = 1.07, 95%CI: 0.47–2.43). In the UKB, the variant m.3010G > A was significantly associated with GBM (OR = 1.32; 95%CI: 1.01–1.73; p = 0.04), but not non-GBM (1.23; 95%CI: 0.78–1.95; p = 0.38); no similar association was observed in the US study. In the US study, the variant m.14798 T > C, was significantly associated with non-GBM (OR = 0.72; 95%CI: 0.53–0.99), but not GBM (OR = 0.86; 95%CI: 0.66–1.11), whereas in the UKB, a positive association was observed between this variant and GBM (OR = 1.46; 95%CI: 1.06–2.02) but not non-GBM (OR = 0.92; 95%CI: 0.52–1.63). None of these associations were significant after adjustment for multiple testing. The association of inherited mtDNA variation, including rare and singleton variants, with glioma risk merits further study.
doi_str_mv 10.1016/j.mito.2022.01.002
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8885975</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567724922000022</els_id><sourcerecordid>2620080341</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-ee1f888d755f5cfae5a7f354442c507d51046a6c525dfed094f7965d3bcad24c3</originalsourceid><addsrcrecordid>eNp9kMtOxCAUhonReH8BF6ZLN60HCqVNjInxnnjZ6JowXGYY26LQmcS3l2ZGoxtXnMB_vsP5EDrCUGDA1em86NzgCwKEFIALALKBdnHNSV4TXm-mmlU854Q2O2gvxjkA5piQbbRTMigJB76L-GNCqJnvdXCyza6eLrJoPhamVyZbynQ3ON9nstdZcPEt8zabts538gBtWdlGc7g-99HrzfXL5V3-8Hx7f3nxkCvK2JAbg21d15ozZpmy0jDJbckopUQx4JphoJWsFCNMW6OhoZY3FdPlRElNqCr30fmK-76YdEYr0w9BtuI9uE6GT-GlE39fejcTU78UaSprOEuAkzUg-LRXHETnojJtK3vjF1GQigDUUFKcomQVVcHHGIz9GYNBjMbFXIzGxWhcABbJeGo6_v3Bn5ZvxSlwtgqYpGnpTBBRudGvdsGoQWjv_uN_AV9Dks4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2620080341</pqid></control><display><type>article</type><title>Mitochondrial DNA sequence variation and risk of glioma</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Samanic, Claudine M. ; Teer, Jamie K. ; Thompson, Zachary J. ; Creed, Jordan H. ; Fridley, Brooke L. ; Burt Nabors, L. ; Williams, Sion L. ; Egan, Kathleen M.</creator><creatorcontrib>Samanic, Claudine M. ; Teer, Jamie K. ; Thompson, Zachary J. ; Creed, Jordan H. ; Fridley, Brooke L. ; Burt Nabors, L. ; Williams, Sion L. ; Egan, Kathleen M.</creatorcontrib><description>•The mitochondrial genome (mtDNA) is polymorphic in human populations.•Inherited variants in mtDNA may play a role in cancer risk and progression.•Array-based genotyping of mtDNA variants in 2 epidemiologic studies of glioma.•Selected mtDNA haplogroups and common mtDNA variants associate with glioma risk.•Complete mtDNA sequencing needed for study of rare and singleton variants. Malignant gliomas are the most common primary adult brain tumors, with a poor prognosis and ill-defined etiology. Mitochondrial DNA (mtDNA) sequence variation has been linked with certain cancers; however, research on glioma is lacking. We examined the association of common (minor allele frequency ≥ 5%) germline mtDNA variants and haplogroups with glioma risk in 1,566 glioma cases and 1,017 controls from a US case-control study, and 425 glioma cases and 1,534 matched controls from the UK Biobank cohort (UKB). DNA samples were genotyped using the UK Biobank array that included a set of common and rare mtDNA variants. Risk associations were examined separately for glioblastoma (GBM) and lower grade tumors (non-GBM). In the US study, haplogroup W was inversely associated with glioma when compared with haplogroup H (OR = 0.43, 95%CI: 0.23–0.79); this association was not demonstrated in the UKB (OR = 1.07, 95%CI: 0.47–2.43). In the UKB, the variant m.3010G &gt; A was significantly associated with GBM (OR = 1.32; 95%CI: 1.01–1.73; p = 0.04), but not non-GBM (1.23; 95%CI: 0.78–1.95; p = 0.38); no similar association was observed in the US study. In the US study, the variant m.14798 T &gt; C, was significantly associated with non-GBM (OR = 0.72; 95%CI: 0.53–0.99), but not GBM (OR = 0.86; 95%CI: 0.66–1.11), whereas in the UKB, a positive association was observed between this variant and GBM (OR = 1.46; 95%CI: 1.06–2.02) but not non-GBM (OR = 0.92; 95%CI: 0.52–1.63). None of these associations were significant after adjustment for multiple testing. The association of inherited mtDNA variation, including rare and singleton variants, with glioma risk merits further study.</description><identifier>ISSN: 1567-7249</identifier><identifier>EISSN: 1872-8278</identifier><identifier>DOI: 10.1016/j.mito.2022.01.002</identifier><identifier>PMID: 35032707</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Brain Neoplasms - genetics ; Case-Control Studies ; DNA, Mitochondrial - genetics ; Glioblastoma ; Glioblastoma - genetics ; Glioma ; Glioma - genetics ; Humans ; Mitochondrial DNA ; UK Biobank</subject><ispartof>Mitochondrion, 2022-03, Vol.63, p.32-36</ispartof><rights>2022 Elsevier B.V. and Mitochondria Research Society</rights><rights>Copyright © 2022 Elsevier B.V. and Mitochondria Research Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-ee1f888d755f5cfae5a7f354442c507d51046a6c525dfed094f7965d3bcad24c3</citedby><cites>FETCH-LOGICAL-c455t-ee1f888d755f5cfae5a7f354442c507d51046a6c525dfed094f7965d3bcad24c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35032707$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Samanic, Claudine M.</creatorcontrib><creatorcontrib>Teer, Jamie K.</creatorcontrib><creatorcontrib>Thompson, Zachary J.</creatorcontrib><creatorcontrib>Creed, Jordan H.</creatorcontrib><creatorcontrib>Fridley, Brooke L.</creatorcontrib><creatorcontrib>Burt Nabors, L.</creatorcontrib><creatorcontrib>Williams, Sion L.</creatorcontrib><creatorcontrib>Egan, Kathleen M.</creatorcontrib><title>Mitochondrial DNA sequence variation and risk of glioma</title><title>Mitochondrion</title><addtitle>Mitochondrion</addtitle><description>•The mitochondrial genome (mtDNA) is polymorphic in human populations.•Inherited variants in mtDNA may play a role in cancer risk and progression.•Array-based genotyping of mtDNA variants in 2 epidemiologic studies of glioma.•Selected mtDNA haplogroups and common mtDNA variants associate with glioma risk.•Complete mtDNA sequencing needed for study of rare and singleton variants. Malignant gliomas are the most common primary adult brain tumors, with a poor prognosis and ill-defined etiology. Mitochondrial DNA (mtDNA) sequence variation has been linked with certain cancers; however, research on glioma is lacking. We examined the association of common (minor allele frequency ≥ 5%) germline mtDNA variants and haplogroups with glioma risk in 1,566 glioma cases and 1,017 controls from a US case-control study, and 425 glioma cases and 1,534 matched controls from the UK Biobank cohort (UKB). DNA samples were genotyped using the UK Biobank array that included a set of common and rare mtDNA variants. Risk associations were examined separately for glioblastoma (GBM) and lower grade tumors (non-GBM). In the US study, haplogroup W was inversely associated with glioma when compared with haplogroup H (OR = 0.43, 95%CI: 0.23–0.79); this association was not demonstrated in the UKB (OR = 1.07, 95%CI: 0.47–2.43). In the UKB, the variant m.3010G &gt; A was significantly associated with GBM (OR = 1.32; 95%CI: 1.01–1.73; p = 0.04), but not non-GBM (1.23; 95%CI: 0.78–1.95; p = 0.38); no similar association was observed in the US study. In the US study, the variant m.14798 T &gt; C, was significantly associated with non-GBM (OR = 0.72; 95%CI: 0.53–0.99), but not GBM (OR = 0.86; 95%CI: 0.66–1.11), whereas in the UKB, a positive association was observed between this variant and GBM (OR = 1.46; 95%CI: 1.06–2.02) but not non-GBM (OR = 0.92; 95%CI: 0.52–1.63). None of these associations were significant after adjustment for multiple testing. The association of inherited mtDNA variation, including rare and singleton variants, with glioma risk merits further study.</description><subject>Adult</subject><subject>Brain Neoplasms - genetics</subject><subject>Case-Control Studies</subject><subject>DNA, Mitochondrial - genetics</subject><subject>Glioblastoma</subject><subject>Glioblastoma - genetics</subject><subject>Glioma</subject><subject>Glioma - genetics</subject><subject>Humans</subject><subject>Mitochondrial DNA</subject><subject>UK Biobank</subject><issn>1567-7249</issn><issn>1872-8278</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kMtOxCAUhonReH8BF6ZLN60HCqVNjInxnnjZ6JowXGYY26LQmcS3l2ZGoxtXnMB_vsP5EDrCUGDA1em86NzgCwKEFIALALKBdnHNSV4TXm-mmlU854Q2O2gvxjkA5piQbbRTMigJB76L-GNCqJnvdXCyza6eLrJoPhamVyZbynQ3ON9nstdZcPEt8zabts538gBtWdlGc7g-99HrzfXL5V3-8Hx7f3nxkCvK2JAbg21d15ozZpmy0jDJbckopUQx4JphoJWsFCNMW6OhoZY3FdPlRElNqCr30fmK-76YdEYr0w9BtuI9uE6GT-GlE39fejcTU78UaSprOEuAkzUg-LRXHETnojJtK3vjF1GQigDUUFKcomQVVcHHGIz9GYNBjMbFXIzGxWhcABbJeGo6_v3Bn5ZvxSlwtgqYpGnpTBBRudGvdsGoQWjv_uN_AV9Dks4</recordid><startdate>20220301</startdate><enddate>20220301</enddate><creator>Samanic, Claudine M.</creator><creator>Teer, Jamie K.</creator><creator>Thompson, Zachary J.</creator><creator>Creed, Jordan H.</creator><creator>Fridley, Brooke L.</creator><creator>Burt Nabors, L.</creator><creator>Williams, Sion L.</creator><creator>Egan, Kathleen M.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220301</creationdate><title>Mitochondrial DNA sequence variation and risk of glioma</title><author>Samanic, Claudine M. ; Teer, Jamie K. ; Thompson, Zachary J. ; Creed, Jordan H. ; Fridley, Brooke L. ; Burt Nabors, L. ; Williams, Sion L. ; Egan, Kathleen M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-ee1f888d755f5cfae5a7f354442c507d51046a6c525dfed094f7965d3bcad24c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>Brain Neoplasms - genetics</topic><topic>Case-Control Studies</topic><topic>DNA, Mitochondrial - genetics</topic><topic>Glioblastoma</topic><topic>Glioblastoma - genetics</topic><topic>Glioma</topic><topic>Glioma - genetics</topic><topic>Humans</topic><topic>Mitochondrial DNA</topic><topic>UK Biobank</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Samanic, Claudine M.</creatorcontrib><creatorcontrib>Teer, Jamie K.</creatorcontrib><creatorcontrib>Thompson, Zachary J.</creatorcontrib><creatorcontrib>Creed, Jordan H.</creatorcontrib><creatorcontrib>Fridley, Brooke L.</creatorcontrib><creatorcontrib>Burt Nabors, L.</creatorcontrib><creatorcontrib>Williams, Sion L.</creatorcontrib><creatorcontrib>Egan, Kathleen M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Mitochondrion</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Samanic, Claudine M.</au><au>Teer, Jamie K.</au><au>Thompson, Zachary J.</au><au>Creed, Jordan H.</au><au>Fridley, Brooke L.</au><au>Burt Nabors, L.</au><au>Williams, Sion L.</au><au>Egan, Kathleen M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mitochondrial DNA sequence variation and risk of glioma</atitle><jtitle>Mitochondrion</jtitle><addtitle>Mitochondrion</addtitle><date>2022-03-01</date><risdate>2022</risdate><volume>63</volume><spage>32</spage><epage>36</epage><pages>32-36</pages><issn>1567-7249</issn><eissn>1872-8278</eissn><abstract>•The mitochondrial genome (mtDNA) is polymorphic in human populations.•Inherited variants in mtDNA may play a role in cancer risk and progression.•Array-based genotyping of mtDNA variants in 2 epidemiologic studies of glioma.•Selected mtDNA haplogroups and common mtDNA variants associate with glioma risk.•Complete mtDNA sequencing needed for study of rare and singleton variants. Malignant gliomas are the most common primary adult brain tumors, with a poor prognosis and ill-defined etiology. Mitochondrial DNA (mtDNA) sequence variation has been linked with certain cancers; however, research on glioma is lacking. We examined the association of common (minor allele frequency ≥ 5%) germline mtDNA variants and haplogroups with glioma risk in 1,566 glioma cases and 1,017 controls from a US case-control study, and 425 glioma cases and 1,534 matched controls from the UK Biobank cohort (UKB). DNA samples were genotyped using the UK Biobank array that included a set of common and rare mtDNA variants. Risk associations were examined separately for glioblastoma (GBM) and lower grade tumors (non-GBM). In the US study, haplogroup W was inversely associated with glioma when compared with haplogroup H (OR = 0.43, 95%CI: 0.23–0.79); this association was not demonstrated in the UKB (OR = 1.07, 95%CI: 0.47–2.43). In the UKB, the variant m.3010G &gt; A was significantly associated with GBM (OR = 1.32; 95%CI: 1.01–1.73; p = 0.04), but not non-GBM (1.23; 95%CI: 0.78–1.95; p = 0.38); no similar association was observed in the US study. In the US study, the variant m.14798 T &gt; C, was significantly associated with non-GBM (OR = 0.72; 95%CI: 0.53–0.99), but not GBM (OR = 0.86; 95%CI: 0.66–1.11), whereas in the UKB, a positive association was observed between this variant and GBM (OR = 1.46; 95%CI: 1.06–2.02) but not non-GBM (OR = 0.92; 95%CI: 0.52–1.63). None of these associations were significant after adjustment for multiple testing. The association of inherited mtDNA variation, including rare and singleton variants, with glioma risk merits further study.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>35032707</pmid><doi>10.1016/j.mito.2022.01.002</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1567-7249
ispartof Mitochondrion, 2022-03, Vol.63, p.32-36
issn 1567-7249
1872-8278
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8885975
source ScienceDirect Freedom Collection 2022-2024
subjects Adult
Brain Neoplasms - genetics
Case-Control Studies
DNA, Mitochondrial - genetics
Glioblastoma
Glioblastoma - genetics
Glioma
Glioma - genetics
Humans
Mitochondrial DNA
UK Biobank
title Mitochondrial DNA sequence variation and risk of glioma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T13%3A04%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mitochondrial%20DNA%20sequence%20variation%20and%20risk%20of%20glioma&rft.jtitle=Mitochondrion&rft.au=Samanic,%20Claudine%20M.&rft.date=2022-03-01&rft.volume=63&rft.spage=32&rft.epage=36&rft.pages=32-36&rft.issn=1567-7249&rft.eissn=1872-8278&rft_id=info:doi/10.1016/j.mito.2022.01.002&rft_dat=%3Cproquest_pubme%3E2620080341%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c455t-ee1f888d755f5cfae5a7f354442c507d51046a6c525dfed094f7965d3bcad24c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2620080341&rft_id=info:pmid/35032707&rfr_iscdi=true